Table 2.
Pharmacotherapy Regimens of COVID-19 Cohort
| Variable | No. (%)a |
|---|---|
| Total DOT | 15,818 |
| Patient-days | 1,589 |
| DOT per patient-day, mean | 9.3 (4.2) |
| Distinct medications per patient, mean (SD) | 19.8 (10.5) |
| Treatment regimens received | |
| Anticoagulation | 182 (94.3) |
| Electrolytes | 162 (83.9) |
| COVID-19 treatment | 150 (77.7) |
| Antimicrobials | 134 (69.4) |
| Antimicrobial duration, mean (SD), db | 3.8 (2.8) |
| Vancomycin | 56 (29) |
| Duration, mean (SD), db | 2.1 (1.6) |
| Antipseudomonal antimicrobial | 67 (34.7) |
| Duration, mean (SD), db | 3 (2.4) |
| Acid-suppressant medications | 108 (56) |
| Corticosteroids | 93 (48.2) |
| Glucose management agents | 72 (37.3) |
| Sedation with or without neuromuscular blockers | 61 (31.6) |
Abbreviations: DOT, days of therapy.
aData are number (percentage) of patients (n = 193) unless otherwise specified
bAnalysis included subset of patients who received therapy.